Clinical trials: Pulmonary Hypertension (PH)
Pulmonary Hypertension Associated With HFpEF
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
The purpose of this study is to assess the efficacy and safety of the study drug, levosimendan (given orally), compared to placebo in participants with pulmonary hypertension with heart failure with preserved left ventricular…
- Trial name
- LEVEL-2 (NCT07288398)
- Testing
- TNX-103
- Where
- 140 sites in United States, Argentina and 13 more
- Volunteers
- 540 people
- Sponsor
- Tenax Therapeutics, Inc.
Pulmonary Arterial Hypertension
A Trial of "APL-9796'' in Adults With Pulmonary Hypertension
The AP13CP02 study is a phase 2, open-label, dose escalation trial to determine how safe and tolerable multiple subcutaneous (SC) injections of APL-9796 are for patients with PH.
- Trial name
- ViTAL-PH (NCT06846554)
- Testing
- APL-9796
- Where
- 6 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- Apollo Therapeutics Ltd
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
This open-label study will evaluate the safety of continued therapy with inhaled treprostinil in participants who have completed Study RIN-PH-304 (NCT03496623).
- Trial name
- PERFECT OLE (NCT03794583)
- Testing
- Inhaled treprostinil solution
- Where
- 32 sites in United States, Israel and 1 more
- Volunteers
- 41 people
- Sponsor
- United Therapeutics
Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Retrospective Data Analysis of Data From the Zurich PH Registry
The collected data from the Zurich Registry for pulmonary Hypertension (PH) are evaluated in a retrospective analysis. This study examines the number of patients and their exact diagnoses who are treated at the University…
- Conditions
- Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Artery Hypertension
- Trial name
- NCT03198910
- Where
- Switzerland
- Volunteers
- 313 people
- Sponsor
- University of Zurich
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF
The objective of this exploratory study is to examine the utility of high resolution computed tomography (HRCT) to measure changes in functional pulmonary imaging parameters as a function of short term a) iNO administration and…
- Conditions
- Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT02267655
- Testing
- inhaled Nitric Oxide - 30 mcg/kg IBW/hr, inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr, inhaled nitric oxide 75 mcg/kg IBW/hr
- Where
- Belgium
- Volunteers
- 8 people
- Sponsor
- Bellerophon
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects
Study ROR-PH-302, ADVANCE CAPACITY, was designed to evaluate the effects of ralinepag therapy on exercise capacity as assessed by change in peak oxygen consumption (VO2) derived from cardiopulmonary exercise testing (CPET) after…
- Trial name
- CAPACITY (NCT04084678)
- Testing
- Ralinepag
- Where
- 33 sites in United States, Argentina and 10 more
- Volunteers
- 10 people
- Sponsor
- United Therapeutics
Interstitial Lung Disease, Precapillar Pulmonary Hypertension
Exploration of Metabolome in Patients With Interstitial Lung Disease and Pulmonary Hypertension With or Without Specific Pulmonary Hypertension Treatment
Fibrosing interstitial lung diseases (FILDs) encompass a group of rare diseases characterized by progressive pulmonary fibrosis leading to respiratory failure.
- Trial name
- BREATH-TPT (NCT07254338)
- Testing
- Blood sampling for metabolomic profiling, Urine sampling for metabolomic profiling
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
The purpose of this study is to evaluate the long-term impact of treprostinil SMI on safety and efficacy by providing it to PH-COPD patients who participated in a preceding Phase 2 or 3 study.
- Trial name
- SUMMIT OLE (NCT07923526)
- Testing
- treprostinil SMI (treprostinil inhalation spray)
- Where
- 15 sites in United States
- Volunteers
- 400 people
- Sponsor
- United Therapeutics
Pulmonary Hypertension
Noninvasive Cardiac Output Measurements in Patients With Pulmonary Hypertension Undergoing Right Heart Catheterization With Acute Vasodilator Testing
Subjects in this study have been diagnosed with pulmonary hypertension (PH) and their doctors have referred them for a right heart catheterization (RHC).
- Trial name
- NCT01275690
- Sponsor
- University of Chicago
Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Latent Pulmonary Hypertension (PH) in Chronic Thromboembolic Pulmonary Hypertension (CTEPH )After Endarterectomy and Influence of Exercise and Respiratory Therapy
Severe CTEPH leads to an impaired physical capacity and a restricted quality of life and poor prognosis. Pulmonary endarterectomy represents the best choice as therapy, when the thrombi are located in the central pulmonary…
- Trial name
- NCT00477724
- Testing
- exercise and respiratory therapy, sedentary control group
- Where
- Germany
- Volunteers
- 35 people
- Sponsor
- Heidelberg University
Pulmonary Arterial Hypertension
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
This is an international, multicenter, randomized, double-blind, placebo-controlled, event driven study in subjects with pulmonary arterial hypertension.
- Trial name
- FREEDOM-EV (NCT01560624)
- Testing
- Treprostinil Diolamine
- Where
- 155 sites in United States, Argentina and 21 more
- Volunteers
- 690 people
- Sponsor
- United Therapeutics
Hypertension, Pulmonary
Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)
The purpose of this study is to assess multiple ascending doses of a new drug (BAY63-2521) given orally, to evaluate if it is safe and can help to improve the well-being, symptoms (e.g.
- Trial name
- NCT00694850
- Testing
- Riociguat (Adempas, BAY63-2521).
- Where
- 5 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Bayer
Pulmonary Hypertension
RUS-registry of PH
Russian National Registry of Patients With Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a multicenter, observational study of the clinical course and disease management of PAH…
- Trial name
- NCT03707561
- Testing
- Right Heart Catheterization (RHC)
- Volunteers
- 200 people
- Sponsor
- Russian Cardiology Research and Production Center
Copd, Hypertension, Pulmonary
Lung Hyperinflation and Response to Pulmonary Vasodilator Therapy
The goal of this retrospective observational study is to evaluate if lung distension disorders can be a predictive factor of bad response to vasodilator therapy in patients with pulmonary hypertension (PH) associated with chronic…
- Conditions
- Copd, Hypertension, Pulmonary, Hyperdistention
- Trial name
- NCT06613321
- Testing
- Respiratory function tests before introduction of vasodilator therapy, 3 month follow up evaluation of response to treatment.
- Where
- France
- Volunteers
- 47 people
- Sponsor
- Central Hospital, Nancy, France
Pulmonary Hypertension
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521, given orally for 16 weeks, in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
- Trial name
- CHEST-1 (NCT00855465)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 89 sites in United States, Argentina and 24 more
- Volunteers
- 262 people
- Sponsor
- Bayer
Pulmonary Fibrosis, Pulmonary Hypertension
Expanded Access for Patients With Pulmonary Hypertension Associated With Pulmonary Fibrosis
An expanded access program that provides INOpulse treatment to patients with serious disease or conditions associated with pulmonary hypertension associated with pulmonary fibrosis who are not able to participate in the Sponsor's…
- Trial name
- NCT05356052
- Testing
- INOpulse
- Sponsor
- Bellerophon
Heart Failure, Pulmonary Hypertension
Rivet PVS Therapy in Group 2 PH-HFpEF
This clinical investigation is a prospective, multicenter, non-randomized, open-label, Early Feasibility Study to evaluate the safety, performance, and initial clinical efficacy of the Rivet PVS therapy in patients with…
- Trial name
- NCT05205265
- Testing
- Rivet Shunt
- Where
- 3 sites in United States
- Sponsor
- NXT Biomedical
Pulmonary Hypertension
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521 given orally for 12 weeks, in patients with symptomatic Pulmonary Arterial Hypertension (PAH).
- Trial name
- PATENT-1 (NCT00810693)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 122 sites in United States, Argentina and 28 more
- Volunteers
- 445 people
- Sponsor
- Bayer
Interstitial Lung Disease, Pulmonary Hypertension
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
- Trial name
- PHINDER (NCT05776225)
- Testing
- Right heart catheterization (RHC)
- Where
- 42 sites in United States
- Volunteers
- 314 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
The Effect of Slow-Paced Breathing on Patient Outcomes in Pulmonary Arterial Hypertension
This study aims to investigate the effects of slow-paced breathing (SPB) intervention applied to patients with pulmonary arterial hypertension (PAH) in the home environment on symptom management (dyspnea, fatigue, sleep quality)…
- Trial name
- NCT07232368
- Testing
- Slow-paced breathing intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 42 people
- Sponsor
- Ege University